Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874488 | 1.00 | FASN (0.72) | FASNTHRB | |
| SCHEMBL2299277 | 0.93 | FASN (0.62) | FASN | |
| SCHEMBL2300771 | 0.91 | FASN (0.66) | FASN | |
| SCHEMBL14346404 | 0.91 | FASN (0.59) | FASNTHRB | |
| SCHEMBL14152133 | 0.91 | FASN (0.59) | FASNTHRB | |
| SCHEMBL2300777 | 0.91 | FASN (0.66) | FASN | |
| SCHEMBL2298682 | 0.90 | FASN (0.61) | FASNTHRB | |
| SCHEMBL2298684 | 0.90 | FASN (0.61) | FASNTHRB | |
| SCHEMBL2300468 | 0.90 | FASN (0.61) | FASN | |
| SCHEMBL2300455 | 0.90 | FASN (0.61) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943484-B1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD (GB) | 2017-10-25 | — | — | EP | disclosed |
| US-9725437-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| US-20160376257-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| US-9340529-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150329524-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2943484-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-8802864-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2014108858-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329524-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885THRB 2475/4885 |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885THRB 2070/4885 |
| US-20160376257-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885THRB 2475/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885THRB 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.